Case report of partial response on second line with Ramucirumab and FOLFIRI in treatment of 74 year old male with metastatic HER2-negative gastric adenocarcinoma
According to the data of the world statistics, gastric cancer (GC) occupies the 5th place by morbidity and the 3rd one by mortality among malignant neoplasms. A significant proportion of patients are elderly patients, the proportion of which in real clinical practice can reach up to 60%. Ramucirumab...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Russo |
| Publicat: |
Remedium Group LLC
2021-08-01
|
| Col·lecció: | Медицинский совет |
| Matèries: | |
| Accés en línia: | https://www.med-sovet.pro/jour/article/view/6258 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|